The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer

Ji, Jie; Xu, Minxue; Qian, Tianyang; Zhu, Shudong; Jiang, Feng; Liu, Zhao-Xiu; Xu, Weisong; Zhou, Juan; Xiao, Mingbing

doi:10.1007/s11033-020-05685-z

Cited by 21 publications

(11 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, inhibition of AKR1B1 inhibited the proliferation, migration, and invasion of colon cancer cells, which in turn impeded liver metastasis of CRC [ 17 ]. In the literature, knockdown of AKR1B1 in HeLa cells was found to inhibit proliferation, migration, and invasion of Hela cells [ 18 ]. Another study found that AKR1B1 was overexpressed in BLBCs but unchanged in tubular cells [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

A Potential Prognostic Biomarker for Glioma: Aldo-Keto Reductase Family 1 Member B1

Zhao

Dong

Huang

et al. 2022

Computational Intelligence and Neuroscience

View full text Add to dashboard Cite

Aldo-keto reductase family 1 member B1 (AKR1B1) plays a vital role in tumor development and is involved in the tumor immune process. However, its role in glioma cell is poorly studied. This study’s aim was to assess the role of AKR1B1 in glioma through bioinformatics analysis. The AKR1B1 expression data and corresponding clinical data of glioma were collected from the Cancer Genome Atlas (TCGA) database. The R packages were used for data integration, extraction, analysis, and visualization. According to the median value of the risk score, all patients were divided into high-risk and low-risk groups to draw the Kaplan–Meier (KM) survival curves and to explore the level of immune infiltration. The expression of AKR1B1 was significantly elevated in glioma tissues compared to normal tissues ( P < 0.001). The high expression of AKR1B1 was significantly associated with WHO grade ( P < 0.001), IDH status ( P < 0.001), 1p/19q codeletion ( P < 0.001), primary therapy outcome ( P = 0.004), and age ( P < 0.05). Kaplan–Meier survival analysis found that OS (HR = 3.75, P < 0.001), DSS (HR = 3.85, P < 0.001), and PFI (HR = 2.76, P < 0.001) were lower in patients with glioma with high AKR1B1 expression than in the group with low AKR1B1 expression. Based on GESA, six pathways (including interferon gamma signaling, signaling by interleukins, cell cycle checkpoints, cytokine receptor interaction, cell adhesion molecules (CAMs), and cell surface interactions) at the vascular wall were identified as significantly different between the two groups. Moreover, highly expressed AKR1B1 was associated with immune cell infiltration. AKR1B1 plays a key role in glioma progression and prognosis and, therefore, serves as a potential biomarker for prediction of patients’ survival.

show abstract

Section: Discussionmentioning

confidence: 99%

A Potential Prognostic Biomarker for Glioma: Aldo-Keto Reductase Family 1 Member B1

Zhao

Dong

Huang

et al. 2022

Computational Intelligence and Neuroscience

View full text Add to dashboard Cite

show abstract

“…Some studies reported that IFITM3 levels were downregulated in cervical cancer. IFITM3 possesses anti-proliferation activities, and is associated with tumor immune escape (Gómez-Herranz et al, 2019;Ji et al, 2020). The aforementioned IRF1, a transcription factor, exhibited an antioncogenic effect and Lee et al (2006) discovered that alternative splicing affecting exons 7, 8, and 9 may be a critical mechanism for negative regulation of IRF-1 expression in cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

The type-1 ribosome-inactivating protein OsRIP1 triggers caspase-independent apoptotic-like death in HeLa cells

Chen

Lossio

Verbeke

et al. 2021

Food and Chemical Toxicology

View full text Add to dashboard Cite

“…The establishment of human endometrial KO cell lines using CRISPR/Cas9 technology confirms the PGs synthase function of AKR1B1 [ 158 ]. In vitro studies have shown that AKR1B1-deficient cervical cancer cell lines exhibit lower proliferation, migration, and invasion than nonmanipulated cells [ 159 ]. Concerning recent reports, AKR1B1 suppression could constrain PGE2 activity and thus disturb cervical carcinogenesis by preventing angiogenesis and cancer cell proliferation as well as inducing apoptosis [ 160 ].…”

Section: Crispr/cas9 In Cancersmentioning

confidence: 99%

CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool

et al. 2022

View full text Add to dashboard Cite

The progress of genetic engineering in the 1970s brought about a paradigm shift in genome editing technology. The clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) system is a flexible means to target and modify particular DNA sequences in the genome. Several applications of CRISPR/Cas9 are presently being studied in cancer biology and oncology to provide vigorous site-specific gene editing to enhance its biological and clinical uses. CRISPR's flexibility and ease of use have enabled the prompt achievement of almost any preferred alteration with greater efficiency and lower cost than preceding modalities. Also, CRISPR/Cas9 technology has recently been applied to improve the safety and efficacy of chimeric antigen receptor (CAR)-T cell therapies and defeat tumor cell resistance to conventional treatments such as chemotherapy and radiotherapy. The current review summarizes the application of CRISPR/Cas9 in cancer therapy. We also discuss the present obstacles and contemplate future possibilities in this context.

show abstract

The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer

Cited by 21 publications

References 51 publications

A Potential Prognostic Biomarker for Glioma: Aldo-Keto Reductase Family 1 Member B1

A Potential Prognostic Biomarker for Glioma: Aldo-Keto Reductase Family 1 Member B1

The type-1 ribosome-inactivating protein OsRIP1 triggers caspase-independent apoptotic-like death in HeLa cells

CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool

Contact Info

Product

Resources

About